IMPORTANT - EIN Presswire is proud to announce the launch of its AI-powered press release generator. Try it now!

There were 1,660 press releases posted in the last 24 hours and 395,629 in the last 365 days.

Rising Incidence of Cancer to Drive Doxorubicin Market at CAGR of 5.3% through 2026: Fact.MR Research

Doxorubicin Market Analysis by Formulation (Lyophilized Doxorubicin Powder & Doxorubicin Solution) By Type (Breast Cancer, Prostate Cancer, Ovarian Cancer, Lung Cancer, Bladder Cancer, Stomach Cancer & Leukemia) By Distribution Channel & Region – Global Market Insights 2026

/EIN News/ -- United States, Rockville MD, May 04, 2022 (GLOBE NEWSWIRE) -- According to a recently published Fact.MR report, the global Doxorubicin Market is projected to grow at a compound annual rate (CAGR) of 5.3% between 2022 and 2026. The market is expected to reach US$ 1.3 Billion by the end of 2026. The demand for Doxorubicin is expected to rise over the forecast period and the market is projected to gain a global market size worth of US$ 1.1 Billion by the end of 2022.

Browse in-depth TOC on "Demand of Liposomal Doxorubicin Market"

84 Tables, 112 Figures and 170 Pages

Cancer is one of the most concerning diseases the human population has ever encountered, and increasing incidence of cancer is driving demand for novel cancer medications. Doxorubicin is one of the most common drugs used in the treatment of several types of cancers such as breast, prostate, ovarian, etc. Increasing awareness about cancer treatments and rising number of cancer patients are projected to drive doxorubicin market potential.

For Critical Insights on Doxorubicin Hydrochloride Market, Request a Sample Report

However, doxorubicin market growth might be restrained to a certain extent owing to increasing awareness of the side effects associated with long-term use of the medication.
Doxorubicin suppliers or focusing on advancing their research and development capabilities to develop novel cancer medications and treatments to maximize their revenue generation potential.
•      In December 2021, Roche, a leading Swiss multinational organization, announced the results of phase III of its POLARIX study that is aimed at depicting a combination treatment approach that reduces the risk of death or disease worsening by nearly 27%. This involved the use of MabThera®/Rituxan® (rituximab) plus cyclophosphamide, doxorubicin, and prednisone (R-CHP) in combination with Polivy® (polatuzumab vedotin).

Which Type of Cancer Accounts for Most Demand for Doxorubicin?

“Ovarian Cancer Accounts for Highest Doxorubicin Consumption”

The world has witnessed a substantial increase in the incidence of ovarian cancer and this trend is anticipated to majorly influence doxorubicin sales across the world. Doxil for ovarian cancer treatment has gained massive popularity in recent years and is anticipated to follow a similar trend throughout the forecast period.

Liposomal Doxil and carboplatin for ovarian cancer are used as a combination treatment. The rising incidence of ovarian cancer will further drive demand for all chemotherapy medications that are crucial to the treatment of this disease.

To learn more about Doxorubicin Market, you can get in touch with our Analyst at

Key Segments Covered in Doxorubicin Industry Research

  • Doxorubicin Market by Formulation :
    • Lyophilized Doxorubicin Powder
    • Doxorubicin Solution
  • Doxorubicin Market by Cancer Type :
    • Breast Cancer
    • Prostate Cancer
    • Ovarian Cancer
    • Lung Cancer
    • Bladder Cancer
    • Stomach Cancer
    • Leukemia
    • Other Types of Cancers

  • Doxorubicin Market by Distribution Channel :

    • Hospital Pharmacies
    • Retail Pharmacies
    • e-Commerce
  • Doxorubicin Market by Region :
    • North America Doxorubicin Market
    • Latin America Doxorubicin Market
    • Europe Doxorubicin Market
    • East Asia Doxorubicin Market
    • South Asia & Oceania Doxorubicin Market
    • MEA Doxorubicin Market

Competitive Landscape

Doxorubicin companies are focusing on launching new products in the nation to maximize their revenue generation potential and increase their market presence.

  • For instance, in September 2020, Zydus Cadila, a leading name in the doxorubicin market, announced that it had received final approval for the commercialization of its generic Doxorubicin Hydrochloride Liposome injection by the FDA (Food and Drug Administration), which is used for the treatment of cancers in the U.S.

Get Customization on this Report for Specific Research Solutions

Key players in the North America Doxorubicin Market

  • Changzhou Kinyond Pharmaceutical Co. Ltd.
  • Cipla Limited
  • Hikma Thymoorgan Pharmazie GmbH
  • Pfizer Inc.
  • Reddy’s Laboratories Ltd.
  • Synbias Pharma AG
  • Janssen-Cilag Pty Limited
  • Meiji Seika Pharma Co. Ltd.

To understand how our report can bring difference to your business strategy, Purchase a copy of this report at

Key Takeaways from the Doxorubicin Market Study

  • In 2022, the doxorubicin market accounts for a valuation of US$ 1.1 Bn.
  • Shipments of doxorubicin are anticipated to increase at a CAGR of 5.3% from 2022 to 2026.
  • The doxorubicin market is set to reach US$ 1.3 Billion by the end of 2026.
  • Increasing incidence of cancer, rising geriatric population, and growing use of doxorubicin in cancer treatment will drive market growth across the forecast period.
  • Side effects associated with the use of doxorubicin are anticipated to hinder market growth over the coming years.
  • Accounting for a major market share of 40.5%, the U.S. doxorubicin industry holds a market value of US$ 443.5 Million in 2022.
  • Sales of doxorubicin in China are predicted to increase at a CAGR of 7.5% through 2026.

Explore Fact.MR’s Coverage on the Healthcare Domain –

Chemiluminescence Immunoassay (CLIA) Analysers Market- The number of tests that use Chemiluminescence Immunoassay Analysers (CLIA) techniques is expected to grow as a result of technical advancements in illness detection, as well as increased demand for preventive diagnosis and treatment monitoring. As a result, demand for high-throughput facilities is increasing. Furthermore, adopting CLIA approaches, large-scale laboratories are capturing a larger portion of the market by exploiting the quality and service limits experienced by small and mid-volume laboratories.

Calprotectin Serum Immunoassay Market- The application of Calprotectin Serum Immunoassay in inflammatory bowel syndromes such as Crohn's disease and ulcerative colitis is the most common driver for the market. Because this serum is secreted at the location of any inflammation in the body, it is used as a biomarker in the identification of many diseases such as CVD, pulmonary fibrosis, and rheumatoid arthritis, among others. Calprotectin is a very strong driver in this industry since immunoassays and rapid diagnosis of numerous diseases can be created, providing the entire market a significant boost.

Immunoassay Market- The database of biomarkers utilized by industry participants to design new assays that detect the onset of a disease or ailment has grown as a result of rapid advances in genomes and proteomics. The global immunoassays market is expected to grow at a rapid pace. With the growing database on genetics and biomarkers of numerous infectious pathogens, key firms are investing in the development of innovative immunoassays in the infectious diseases area. For the diagnosis of infectious disorders, immunoassay analyzers such as enzyme-linked immunosorbent assay (ELISA) and others are preferred.

About Us:
Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Our sales offices in United States and Dublin, Ireland. Headquarter based in Dubai, UAE. Reach out to us with your goals, and we’ll be an able research partner.

Mahendra Singh
Japan Sales Office
4-1-1 Nakano,
9F Nakano Sunplaza
Tokyo, 164-8512

Primary Logo